MEI Pharma Files Q3 2025 10-Q, Details Revenue and Agreements
Ticker: LITS · Form: 10-Q · Filed: May 13, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, collaboration, asset-purchase
Related Tickers: KYC
TL;DR
MEI Pharma's Q3 2025 10-Q shows revenue from collaborations and contracts, with key deals like the Oct 2024 asset purchase and July 2023 Kyowa Kirin partnership.
AI Summary
MEI Pharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenue from collaboration agreements and contract with customers. Key events include an Asset Purchase Agreement on October 22, 2024, and a collaboration with Kyowa Kirin Co. on July 14, 2023. The filing also details general and administrative expenses and retained earnings for the period.
Why It Matters
This filing provides insight into MEI Pharma's financial performance and ongoing business development activities, including significant agreements that could impact future revenue streams.
Risk Assessment
Risk Level: medium — The company's financial health and future prospects are tied to the success of its drug development pipeline and strategic partnerships, which carry inherent risks.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for this filing.)
- 2025-05-13 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2024-10-22 — Asset Purchase Agreement Date (A significant corporate action mentioned in the filing.)
- 2023-07-14 — Kyowa Kirin Co. Collaboration Date (Marks the initiation of a key partnership.)
Key Players & Entities
- MEI Pharma, Inc. (company) — Filer
- March 31, 2025 (date) — Reporting Period End Date
- October 22, 2024 (date) — Asset Purchase Agreement Date
- July 14, 2023 (date) — Kyowa Kirin Co. Collaboration Date
- Kyowa Kirin Co. (company) — Collaboration Partner
FAQ
What was MEI Pharma's revenue from collaboration agreements for the nine months ended March 31, 2025?
The filing indicates revenue from collaboration agreements for the period from July 1, 2024, to March 31, 2025, but specific dollar amounts are not detailed in this excerpt.
What is the nature of the Asset Purchase Agreement dated October 22, 2024?
The filing mentions an 'Asset Purchase Agreement' on October 22, 2024, but the specific assets or terms are not detailed in this excerpt.
What is the current status of the collaboration with Kyowa Kirin Co. initiated on July 14, 2023?
The filing references the Kyowa Kirin Co. collaboration initiated on July 14, 2023, but does not provide an update on its current operational status or progress in this excerpt.
What were MEI Pharma's general and administrative expenses for the quarter ended March 31, 2025?
The filing lists 'General And Administrative Expense' for the period January 1, 2024, to March 31, 2024, and January 1, 2025, to March 31, 2025, but specific figures are not provided in this excerpt.
What is the company's fiscal year end?
MEI Pharma, Inc.'s fiscal year ends on June 30.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding MEI Pharma, Inc. (LITS).